MBX Biosciences received a Buy rating upgrade following strong Phase 2 results for its drug canvuparatide, which treats hypoparathyroidism with once-weekly dosing and strong efficacy. This positions MBX to challenge the current standard treatment and potentially earn blockbuster revenues. The company also has an early-stage obesity treatment pipeline targeting a large market with monthly dosing technology, though this area carries higher development risks. With $418 million in cash, a $2.84 billion market cap, and several upcoming catalysts, MBX offers significant upside potential despite risks in Phase 3 trials and obesity drug development.
MBX Biosciences is the subject of a rating upgrade after promising Phase 2 trial results. For readers following the US health sector, here is Pluang's market snapshot as of Sep 24, 2026 02:11 WIB: out of 100 priced health stocks, only 10 rose while 89 fell. DNA (Ginkgo Bioworks Holdings Inc) dropped 8.11% to USD 8.61 with a typical hold time of 10 days and a 70% sell order activity, contrasting with SANA (Sana Biotechnology Inc) which fell 7.51% to USD 3.08 but saw 93% buy orders and a longer hold time of 22 days. TXG (10X Genomics Inc) traded at USD 75.08, down 6.96%, with a nearly balanced order activity and the longest hold time of 94 days among these movers.
NeoVolta reported a weak Q4 with revenue dropping to $13,460 and a loss of $0.24 per share, missing analyst expectations. Despite this, full-year revenue rose 58% to $13.3 million as the company expanded beyond residential markets. The Q4 loss widene...
BlackBerry is expected to report Q3 earnings with an EPS of $0.04 and revenue around $143.55 million, in line with company guidance. The company has a strong track record of beating earnings estimates, driven by growth in its QNX automotive software ...
On September 23, Jaguar Health's stock plunged about 74%, reversing a prior gain, without any confirmed negative news. Alkami Technology's shares fell 19% after ending a strategic review and deciding to remain independent. Other stocks like Cullinan ...
Wheeler REIT (WHLR) surged 190.91% after a 1-for-9 reverse stock split, though no new catalyst was confirmed. Artelo Biosciences (ARTL) rose 74% following a provisional patent application for its obesity drug candidate ART27.13, based on early mouse ...
Costco Wholesale announced $93.9 billion in net sales for its fiscal Q4, up 11.3% from last year, with comparable sales rising 9.4%. The full earnings report on September 24 will reveal membership fees, total revenue, expenses, and profit details. An...
